Liangliang Qiao

机构：Guangzhou University of Chinese Medicine

发表论文 13 篇 · 总被引 634 次 · h-index 7

代表论文

• Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) (2022 · Journal of Clinical Oncology · 被引 452)
• Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study (2024 · Hepatology · 被引 57)
• Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma (2024 · JAMA Oncology · 被引 56)
• Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis (2022 · Cancer Medicine · 被引 17)
• Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus (2024 · JAMA Surgery · 被引 15)
• Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer (2025 · JAMA Oncology · 被引 13)